JJ
Therapeutic Areas
MediciNova Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MN-166 (ibudilast) | Progressive Multiple Sclerosis | Phase 3 |
| MN-221 | Acute Exacerbations of Asthma | Phase 3 |
| MN-001 | Liver Fibrosis (NASH) | Phase 2 |
| MN-029 | Oncology (unspecified) | Not Disclosed |
| MN-305 | Not specified | Not Disclosed |
| MN-246 | Not specified | Not Disclosed |
| Portfolio Candidate | Solid Tumor Cancers | Preclinical/Clinical |
Leadership Team at MediciNova
YI
Yuichi Iwaki
President and Chief Executive Officer, and Founder
KM
Kazuko Matsuda
Chief Medical Officer
DH
David H. Crean
Chief Business Officer
YI
Yuichi Iwaki
Member of the Board of Directors
HN
Hideki Nagao
Member of the Board of Directors
KM
Kazuko Matsuda
Member of the Board of Directors
CB
Carolyn Beaver
Member of the Board of Directors